As an accomplished apoptosis researcher and former CEO of the Sanford-Burnham Medical Research Institute, John Reed has spent much of his career championing academic drug discovery. Last year, however, he started in his new role as Head of Pharma Research & Early Development at Roche, one of the world's largest drug developers. Flush with resources and ideas, he told Asher Mullard about his plans to tweak Roche's therapeutic focus and its approach to clinical development and the externalization of innovation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
John Reed. Nat Rev Drug Discov 13, 170–171 (2014). https://doi.org/10.1038/nrd4262
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4262
